Darcy Lewis

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.

Multiple gene signature assays have been developed that supply prognostic information for decisions on adjuvant chemotherapy and whether therapy should be of extended duration.